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PE  96.643/fin. The  Committee  on  the  Environment,  Public  Health  and  Consumer  Protection 
hereby  submits  to  the  European  Parliament  the  following  motion  for  a  resolution 
together  with  explanatory  statement: 
A. 
MOTION  FOR  A RESOLUTION 
on  the  export  of  pharmaceutical  products  to  the  Third  World 
having  regard  to  the  Motion  for  a  Resolution  tabled  by  Ms  QUIN  and  Mr  ADAM 
on  the  export  of  durgs  from  the  EEC  to  the  countries  of  the  Third  World 
(Doc.  No.  2-565/84), 
having  re~ard to  its  Resolution  on  the  export  of  pesticides  to  the  Third 
1  World  (Doc.  458/83)  , 
having  regard  to  the  Council  of  Europe's  Parliamentary  Assembly  Report  by 
Mr  LTND  on  the  sale  of  European  Pharmaceutical  products  in  the  countries  of 
the  Third  World, 
having  regard  to  the  report  of  the  Committee  on  the  Environment,  Public  Health 
and  Consumer  Protection  and  the  Opinion  of  the  Committee  on  Development  and 
Cooperation  (Doc.  A 2-36/86), 
A.  Aware  of  the  widespread  public  concern  in  Europe  about  the  problem  of  ill-
health  in  the  Third  World, 
B.  Aware  that  more  than  half  of  the  world  population  suffers  from  a  chronic 
lack  of  proper  medical  care, 
C.  Noting  that  industrial  countries  which  account  for  15%  of  world  population 
consume  more  than  50%  of  pharmaceutical  products, 
D.  Noting  also  that  almost  90%  of  world  pharmaceutical  production  is  based 
in  industrialised  countries  so  that  Third  World  countries  depend  almost 
entirely on  imported  pharmaceutical  products  and  because  of  this  it  is 
important  that  international  standards  should  exist  in  relation  to  the 
quality  and  usage  of  these  products, 
E.  Aware  of  the  World  Health  Organisation  certification scheme  on  the  quality of 
pharmaceutical  products  moving  in  international  commerce, 
1  OJ  No  C 307  of  17.11.83,  p.  109 
- 5  - PE  96.643/fin. F.  Aware  of  the  World  Health  Organisation's  policy  and  Action  Programme  on 
Essential  Drt.gs, 
G.  Aware,  too,  of  the  important  part  ~ich both  the  Lome  Convention  and  the 
other  agreements  Linking  the  European  Community  to  the  developing  regions  or 
countries  can  also  play  in  respect  of  this  problem, 
H.  Notes,  with  approval,  the  outstanding  work  being  done  by  development  and 
health  voluntary  workers  <both  lay  and  religious)  from  the  Member  States 
throughout  the  Third  World, 
r.  Having  regard  to  the  economic  importance  of  the  pharmaceutical  industry  to 
the  Furopean  Community  and  that  the  European  Pharmaceutical  Industry  subscribes 
to  an  International  Code  of  Pharmaceutical  Marketing  Practices  which  was 
adopted  by  the  International  Federation of  Pharmaceutical  Manufacturers  Asso·· 
ciations  in  1981, 
J.  Aware  that  within  the  Community,  Legislation  already  exists to ensure  that 
pharmaceutical  products  are  manufactured  to  high  quality  standards  and  require 
authorisation before  being  placed  on  the  market, 
~ Conscious  of  the  overwhelming  shortage  of  high  quality,  safe,  effective 
and  inexpensive  essential  drugs  throughout  much  of  the  Third  World, 
1.  Believes  that  national  drugs  policies  should  be  based  on  the  concept  of  essential 
drugs,  Ci.e.  a  basic  List  of  those  drugs  which  are  needed  for  health  care 
of the  majority  of  the  population  and  should  be  available  at  all  times  in 
adequate  amounts  and  in  the  proper  dosage  forms); 
2.  Calls  on  the  Community,  as  well  as  its  Member  States  individually,  through 
participation  in  the  World  Health  Organisation,  to assist  Third  World  countries 
in 
establishment  of  a  national  drug  regulatory  authority  in  every  country, 
the  provision  of  complete  and  unbiased  information  in  the  form  of  W.H.O. 
guidelines  on  minimum  requirements  for  national  drug  regulation  so  that  all 
countries  would  be  in  a  position  to  set  up  such  mechanisms  beginning  with 
drug  registration; 
- 6  - PE  96.643/fin. 3.  Welcomes  the  World  Health  Organisation  commitment  to guidelines  on  ethical 
norms  on  drug  advertising  and  calls  on  all  governments  to  implement  and 
enforce  such  'norms'; 
4.  Supports  the  W.H.O.  Certification Scheme  on  the quality of  pharmaceutical 
products  moving  in  intern~tional  commerce  and  believes  that  the  scheme  should 
both  be  strengthened  to  include  criteria of  drug  effectiveness  and  to  cover 
the  active  ingredients  of  pharmaceutical  compounds  and  should  be  more  availed 
of  by  Third  World  countries  and  recommends  that  the  Commission  should  urge 
Member  States  to  participate fully  in  the  extended  scheme; 
5.  Points  out  that  the  existing  sources  of  information  within  the  W.H.O. 
and  the  United  Nations,  such  as: 
the  W.H.O.  Bulletin  on  pharmaceutical  products, 
the  International  Conference  of  Registration  Authorities, 
the  U.N.  Secretariat's  List  of  proscribed,  withdrawn  or  severely  restricted 
products,  drawn  up  under  the  aegis  of  the  W.H.O., 
should  also  be  more  widely  used  by  the  countries  of  the  Third  World; 
I 
6.  Calls  on  the  Community  Institutions  to  develop  and  adopt  a  directive  to 
approximate  the  Member  States'  Laws,  regulations  and  administrative  provisions 
relating  to  the  export  of  pharmaceutical  products  with  the  intention  of 
prohibiting  the  export  of  products  which  are  banned,  withdrawn,  or  subject 
to  special  restriction  within  the  Community  market  or  which  have  not  been 
registered  for  that  market,  unless  authorities  in  the  importing  country 
specifically  request  the  product  having  first  been  fully  informed  of  the 
controls  on  its  use  in  Europe,  and  that  all  notifications  and  responses  by 
importing  countries  should  be  published  by  the  Commission; 
7.  Requests  that  a  rule  be  included  in  the  above-mentiqned  directive  providing 
that  the  scientific  committee  on  drugs  be  given  authority  to  determine 
what  is  to  be  understood  by  special  restrictions.  In  the  Light  of  how 
the  special  restrictions  are  defined,  this  committee  shall  draw  up  a  List 
of  drugs  subject  thereto.  This  List  shall  be  regularly  updated  and  published; 
- 7  - PE  96.643/fin. 8.  Requests  the  Commission  that  this directive  should  also  ensure  the  supply 
of  complete  product  information  of  a  standard equivalent  to  that  available 
in  Europe  to  be  provided  for  users  and  prescribers  in  the  principal  Language 
of  the  importing  country; 
9.  Asks  the  Commission  to  investigate  whether  a  system  can  be  devised  whereby, 
by  means  of  a  statutory  ruling,  sales  of  products  which 
(a)  are  found  to  have  been  placed  on  the  market  in  violation of 
the  directive, 
(b)  are  found  to  represent  an  immediate  risk  to  public  health,  owing  to 
incomplete  or  incorrect  information, 
(c)  have  to  be  regarded,  on  the  basis  of  new  information,  as  dangerous 
to public  health, 
are  stopped  and  such  products  are  withdrawn  from  the  market  as  soon  as  possible, 
not  only  in  the  Member  States  but  in all  countries  in  which  they  are  marketed; 
10•  Commends  the  W.H.O.  Action  Programme  on  Essential  Drugs  and  Vaccines  and 
calls  on  the  Community  and  the  individual  Member  States  to  provide 
additional  resource  support  for  that  programme  and  to  implement  its 
recommendations  in  health  related  aid  programmes; 
11.  Calls  on  both  the  Community  and  the  governments  of  Third  World  countries 
to  take  stringent  measures  to prevent  the  counterfeiting  of  pharmaceutical 
products  ; 
1l  Calls  for  increased  funds  for,  and  a  more  co-ordinated  approach  towards, 
research,  by  Member  State  Governments,  medical  and  academic  institutions 
and  the  pharmaceutical  industry,  to  find  cures  for  tropical  diseases; 
1l  Instructs  its President  to  forward  this  resolution  to  the  Commission, 
the  CounciL,  the  Council  of  Europe,  the  World  Health  Organization,  the 
ACP  countries  and  the  countries  Linked  to  the  EEC  by  other  agreements. 
- 8  - PE  96.643/fin. B. 
EXPLANATORY  STATEMENT 
1.  There  is  a  widespread  public  concern  in  Europe  about  the  problems  of  the  Thi~d 
i 
World,  most  recently  highlighted  by  the  European  response  to  famine. 
Europeans  are  increasingly distressed  and  baffled  by  the  fact  that  millions  of 
people  die  annually  in  the  Third  World  from  often  relatively  'simple diseases' 
which  in  Europe  are  minor  and  easily  curable  ailments.  Diarrhoea  alone  is  the 
Largest  single killer of  children  under  the age  of  five  with  almost  8  million 
deaths  a  year. 
There  is,  at  present,  an  inequitable distribution of  health  resources  in  the  world, 
particularly  in  relation to  supplies  of  drugs.  The  most  urgent  need  regarding  drugs 
at  this  stage  is  to  make  it possible  for  the  vast  majority  of  the  world's  people 
who  Live  in  the  developing  countries  to  have  access  at  a  cost  they  can  afford 
to  those  30  or  40  drugs  that  are  vital  to  them  as  part  of  their  primary  health 
care,  and  to  ensure  that  these  drugs  are  used  rationally. 
1n  the  industrialised  countries  there  are  thousands  of  drugs  on  the  market,many  of 
them  identical  or  highly  similar  but  sold under  different  names,  and  many  of  them 
incorporating  a  variety  of  active  ingredients.  In  the  Third  World,  while  the 
situation  in  some  urban  areas  may  resemble  that  in  the  industrialised world,  the 
vast  ma.iority  of  people  who  Live  in  rural  areas  have  Little or  no  systematic 
access  to  drugs. 
Also  in  developing  countries,  doctors  are  few  and  far  between.  Most  people  rely 
for  health  care  mainly  on  other  categories of health  workers  such  as  nurses  and 
pharmacists,  but  more  usually  on  non-professional  health  workers  with  Limited 
training or  traditional  practitioners.  There  are  few,  if any,  pharmacies 
outside  the  towns,  whether  private or government  owned,  and  other  arrangements 
have  to  be  made  to  ensure  the  availability of  drugs,  in  places  such 
as  hospital  outpat~~nt  .. departments,  dru~ 
drug  co-operatives  and  small  village  shops. 
corners  in  health  centres,  village 
The  inadequacy  of  the  health  infra-
structure  and  the  weakness  of  distribution,  transport  and  communication  systems 
make  it extremely  d·ifficult  for  drugs  to  reach  those  people  who  need  them  even 
if drugs  are  centrally availabe. 
- 9  - PE  96.643"fin. In  both  developing  and  developed  countries  a  comprehensive  national  drug 
policy  forming  an  integral  part  of  a  national  health  policy  is the  exception 
rather  than  the  rule. 
Sometimes,  the  most  appropriate  therapy  does  not  include  drugs.  But,  when  it 
does,the  rational  use  of  durgs  demands  that  the  appropriate  drug  be  prescribed, 
that  it be  dispensed  correctly,  and  that  it  be  taken  in  the  right  dose  at  the 
right  intervals  and  for  the  correct  Length  of  time.  The  appropriate  drug 
must  be  effective,  and  be  of  acceptable  quality  and  safety. 
2.  Poverty,  of  course,  is  the  root  cause  of  ill-health  in  developing  countries 
where  the  majority  of  the  population  suffers  from  a  chronic  Lack  of  medical 
care.  The  types  of  health  care  problems  in  these  countries  are quite  different 
from  those  in  industrialised  countries.  In  the  Third  World,  infectious 
diseases  remain  a  major  cause  of  death  and  almost  one  billion  people  Ca  quarter 
of  the  worlds  population)  are  affected  or  threatened  by  tropical disease. 
Currently,  treatment  facilities  and  medication  are  simply  not  available  in  time 
to  a  majority  of  people.  The  reasons  for  this  range  from  a  Lack  of  funds  and 
·medical  personnel,  inadequate  transport  facilities  and,  it must  be  added, 
inefficency  and  corruption.  It  is  also,  unfortunately  apparent  that  health 
care  is  not  accorded  the  high  priority it deserves  by  certain developing 
countries,  ranking  lower  on  the  national  budget  scale  than  military  spending. 
3.  The  availability of  pharmaceutical  products  is  a  central  element  in  the 
establishment  and  maintenance  of  equitable  health  care  systems. 
Industrial  countries  which  account  for  only  15%  of  world  population  consume 
more  than  50%  of  ph~rmaceutical products.  90%  of  world  pharmaceutical 
production  is  based  in  industrialized  countries. 
The  pharmaceutical  industry  is  of  major  importance  to  the  economy  of  the 
European  Communities,  employing  almost  half-a-million  people,  many  of  whom  are 
highly  qualified.  Pharmaceuticals  make  an  important  contribution  to  the 
balance  of  trade  in  the  EC  three  Member  States  CUK,  FRG  and  France)  are  among 
the  top  five  pharmaceutical  exporting  countries  in  the  world.  Ireland  is  in 
tenthpositio~. 
- 10  - PE  96.643/fin. Within  the  European  Community,  Legislation exists  to  ensure  that  pharmaceutical 
products  are  manufactured  to  high  quality  standards  and  are  properly  tested 
before  being  placed  on  the  market.  EEC  Directive  319  of  1975  requires  that 
'all medicinal  products  to  be  manufactured  in  the  Community  require  authori-
sation,  and  official  inspections  take  place  to  ensure  compliance  with  proper 
manufacturing  standards.  In  addition,  an  authorisation  to place  products  on 
the  market  is  required  for  those  medicinal  products  which  are  to  be  sold  in the 
Community'. 
4.  Since  Third  World  countries  import  almost  all of  their drugs  it  is  important 
that  international  standards  should  exist  in  relation  to  the  quality  and  usage 
of  pharmaceutical  products.  Countries  Lacking  a  comprehensive  and  fully  inde-
pendent  system  of  drug  control  are  Limited  in  their capability  to  assure  the 
quality,  safety  and  efficacy  of  pharmaceutical  products  which  they  import; 
and  where  there  is  no  effective  system  of  drug  registration  the  sale of 
unlicensed  and  mislabelled  products  will  remain  unchallenged. 
These  deficiencies  can  be  corrected  in  Locally  manufactured  products  only  by 
improving  or  indeed  establishing national  control  mechanisms.  When  a  product 
is  imported,  however,  the  regulatory  authority  in  the  country  of origin  should 
be  in  a  position  to  provide  an  assurance  on  the  conditions  under  which  it  is 
manufactured  together  with  information  on  whether,  and  for  what  purpose,  it 
is  .wai lable  in  the  domestic  market. 
The  World  Health  Organisation  Certification  Scheme  on  the  Quality  of 
Pharmaceutical  Products  Moving  in  International  Commerce  was  adopted  in  1975 
and  it provides  a  simple  administrative  mechanism  whereby  importing  countries 
can: 
(i)  ascertain  whether  a  given  product  has  been  registered  for  marketing 
in  the  exporting  country  and,  when  appropriate,  request  an  explanation 
of  the  reason  registration  has  not  been  accorded; 
(ii)  obtain  assurance  that  the  manufacturing  plant  in  which  the  product 
is  produced  is  subject  to  periodic  inspection  and  conforms  to  requirement 
for  good  practices  in  the  manufacture  and  quality  control  of  drugs  as 
recommended  by  W.H.O. 
- 11  - PE  96.643/fin. ( i i i )  obtain details  of  the  inspection  ~nd control  procedures 
exercised  by  the  authority  in  the  exporting  country  and  request 
inquiries  to  be  instituted by  the  exporting  authority  should  a 
certified product  be  found  to  be  of  unacceptable  quality. 
About  100  countries  out  of  158  participate  in  the  scheme.  The  scheme  stresses 
the  role  of  the  importing  country  providing  a  right  for  it to  obtain  information. 
Increased  use  of  the  scheme  should  be  encouraged.  Also  possible  ways  to 
increase  the  strength  and  scope  of  the  scheme  include  its extension  to  cover 
'active  ingredients'  as  well  as  finished  pharmaceutical  products ·and  the 
creation  of  an  international  inspectorate  of  independent  arbitration  procedures 
to  supervise  its  implementation. 
5.  The  marketing  of  drugs  by  the  pharmaceutical  industry  has  been  the  subject 
of  much  criticism because  of  its alleged aggresivity  and  bias  and  there  is 
wide  agreement  on  the  need  for  recognised  norms. 
It  is  not  easy  for  prescribers  to  select  drugs  properly  and  use  them  wisely 
when  they  face  a  bewildering  amount  and  variety of  information  and  consumers 
believe  that  there  is  'a pill  for  every  ill'.  To  inform  and  influence 
prescribers  and  the  public,  manufacturers  and  distributors  resort  to  various 
forms  of  promotion  such  as  advertising,  offering  samples,  using  sales 
representatives,  sponsoring  symposia,  and  even  providing  financial  and  other 
incentives.  Some  of  this  conforms  to acceptable  ethical  standards;  some  does 
not. 
The  European  Community  pharmaceutical  industry  is  represented  internationally 
by  the  International  Federation  of  Pharmaceutical  Manufacturers  Associations 
_<IFPMA)  and  subscribes  to  its Code  of  Pharmaceutica_l  Marketing  Practices. 
This  code,  which  is  voluntary,  is  the  industry's  policing  system  and  was 
adopted  in  1981.  It  seeks  to  ensure  that  all  products  are  issued  according 
to  adequate  procedures  and  strict quality  assurance,  that  qualities  claimed 
for  products  are  based  on  valid scientif·ic  evidence,  and  factual  and  honest 
information  is  provided  about  them  to  medical  officials  and  the  public. 
In  1982,  the  IFPMA  set  up  procedures  to  handle  complaints  alleging  violations 
of  the  code.  In  1983,  IFPMA  took  the  decision  to  make  public  the  results  of 
the  consideration  of  all  complaints  made  under  the  code. 
- 1 2  -The  procedures  for  dealing  with  complaints  are  as  follows: 
In  the  case  of  complaints  made  directly  to  IFPMA,  these  are  forwarded  for 
consideration  to  the  Association  {s)  concerned.  Their  findings  are  then 
passed  on  the  IFPMA  whose  responsibility  it  is  to  respond  to  the  complainant. 
In  addition,  an  ex-officio  committee  of  the  IFPMA  council,  consisting  of  the 
President,  the  two  Vice  Presidents  and  the  Executive  Vice  President,  oversees 
all  matters  involving  the  Code.  Where  complains  are  addressed  to  member 
Associations,  they  are  replied  to  by  the  Member  Association  (s) 
after consultation  with  the  company  or  companies  involved. 
International  companies,  through  membership  by  the  parent  company  of  an  IFPMA 
Member  Association,  are  regarded  as  being  bound  by  the  Code  in  all  countries 
in  which  they  operate  whether  or  not  there  is  an  IFPMA  1~ember Association  in 
that  country. 
Member  Associations  have  been  advised  to  set  up  their  own  procedures  for  moni-
toring  the  code  and  many  of  them  have  done  so  IFPMA  has  had  instances of 
unofficial  complaints  that  have  been  forwarded  to  the  Federation  by  interested 
parties,  including officials of  WHO,  and  the  Federation's  Secretariat  is  itself 
active  in  Looking  for  possible  breaches  of  the  Code.  The  outcome  of  cases 
considered  under  the  Code  is  made  public  by  means  of  regular  Status  Reports. 
According  to  the  IFPMA,  to  date  in  all  cases  where  claims  of  breaches  of  the 
Code  by  companies  in  membership  of  IFPMA  ~ember Associations  have  been  upheld, 
the  company  concerned  has  agreed  to  remedy  the  Lapse. 
1he  IFPMA  Code  has  been  criticised because  it carries  no  penalty  provisions: 
Material  penalties  can  only  be  imposed  with  the  backing  of  the  Law  and  this  Law 
would  have  to  be  national  Law. 
Neither  the  IFPMA  nor  WHO  can  impose  direct  penalties  on  companies  violating 
the  Code  unless  national  Legislation  existed  to  enable  this  to  be  done.  The 
only  sanction  that  the  IFPMA  can  impose  is  adverse  publicity which  is  a  matter 
of  concern  for  the  reputation of  international  companies.  Also  the  IFPMA 
Member  Associations  can,  if  they  wish  and  some  do,  have  a  provision  in  their 
statutes  allowing  them  to  expel  any  company  refusing  to  abide  by  the  IFPMA 
Code. 
Another  criticism  is  that  not  all  the  world's  pharmaceutical  industry  is 
covered  through  IFPMA  membership. 
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applies  throughout  the  world  to all  companies  belonging  to  those  fifty 
members.  It  is  estimated  that  about  80%  of  the  pharmaceuticals  sold outside 
the  Warsaw  Pact  countries  and  China  fall  within  its scope. 
The  Code  has  been  criticised as  weak  and  ineffective.  In partial  reply  to 
su~h criticism multinational  companies  have  stated that  even  if policy decisions 
are  taken  centrally,  the  decisions  may  not  be  carried out  by  all subsidiaries, 
and  that  it  is  impossible  for  the  corporate  headquarters  of  a  multinational 
company  to  know  all  the  time  what  is  happening  in  every  market.  In  many 
developed  countries  there  are  regulatory  constraints on  promotional  methods, 
but  in  many  Third  World  countries  Governments  are  not  yet  in  a  position  to 
assume  that  responsibility.  This  places  even  greater  emphasis  on  the 
necessity  for  industry  to  apply  in  these  countries  the  same  norms  that  they 
apply  in  developed  countries. 
At  international  Level,  the  twenty-first  World  Health  Assembly  in  1968 
adopted  a  series of  ethical  and  scientific  criteria  to  be  truthful  and  reliable 
and  statements  should  be  supported  by  adequate  scientific  evidence.  It  is 
stipulated  that  promotional  material  should  maintain  a  fair  balance  between 
effectiveness  on  the  one  hand  and  adverse  reactions  and  contra-indications  on 
the  other.  It  should  provide  a  full  designation  of  the  nature  and  content 
of  active  ingredient(s)  per  dose  using  generic  or  non-proprietary  names. 
It 'is  further  stipulated that  advertisements  to  the  public  should  not  be 
permitted  for  prescription  drugs  for  the  treatment  of  conditions  which  can  be 
treated  only  by  a  doctor  or  in  a  form  that  could  provoke  fear  or distress or 
that  claims  infallibility or  suggests  that  the  drug  is  recommended  by  members 
of  the  medical  profession. 
The  Rapporteur  welcomes  WHO  plans  to  strengthen  and  improve  such  guidelines 
but  stresses  that  it  is  up  to  national  Governments  to  adopt,  implement  and 
enforce  them. 
6.  In  1977,  the  World  Health  Organisation  Launched  its Policy  on  Essential  Drugs 
and  Vaccines:  The  Policy  is  based  on  the  concept  that  essential  drugs  are 
those  that  satisfy  the  health  care  needs  of  the  majority  of  the  population; 
they  should  therefore  be  available  at  all  times  in  adequate  amounts  and  in  the 
appropriate  dosage  forms.  The  choice  of  such  drugs  depends  on  many  factors, 
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the  training  and  experience  of  the  available  personnel;  the  financial  resources; 
and  genetic,  demographic  and  environmental  factors:  Only  those  drugs  should 
be  selecteu  for  which,  srund  and  adeqJate  data  on  efficacy and  safety are available fran  adeq..Jate 
,-d inical studies art:!  for  which  Pvirlf>nce  of performance  in  general  use  in a variety of medical 
settings has  been  obtained. 
The  stability of  the  drugs  under  the  anticipated  conditions  of  storage  must 
be  established.  Where  two  or  more  drugs  appear  to  be  approximately  similar 
in  the  above  respects,  the  choice  between  them  should  be  made  on  the  basis  of 
a  careful  evaluation  of  their  relative efficacy,  safety quality,  price  and 
availability.  In  the  great  majority  of  cases,  essential  drugs  should  be 
formulated  as  single  compounds. 
An  essential  drugs  List  may  be  modified  or  augmented  according  to  the 
specific  needs  of  a  country,  and  does  not  imply  that  no  other  drugs  are 
necessary. 
The  158  Member  Countries  of  the  W.H.O.  contribute  financially  to  the  Essential 
Drugs  Programme  and  many  European  pharmaceutical  companies  provide  technical 
assistance,  training  and  drugs  at  preferential  prices. 
After  the  establishment  of  the  1977  W.H.O.  model  List  of  Essential  Drugs, 
many  developing,  but  no  industrialised,  countries  made  attempts  to  establish 
national  Lists  suited  to  their  own  needs.  Today,  the  number  of  countries  with 
Lists  of  essential  drugs  or  national  formularies  containing  chiefly essential 
drugs  exceeds  80. 
The  establishment  of  a  national  List,  however,  does  not  necessarily  Lead  to 
implemation  of  the  concept  of  essential  drugs.  In  some  developing  countries 
the  new  list  of  essential  drugs  became  just  another  List  added  to  the  many 
existing  Lists!  The  importation,  distribution,  and  use  of  expensive  non-
essential  drugs  continued  as  before  in  the  growing  private  sector.  In  some 
countries  <such  as  Kenya,  Mozambique,  Tanzania,  etc.),  the  List  was  applied 
vigorously  to  the  primary  health  care  system. 
The  Action  Programme  was  formally  established  in  1981  as  an  operational 
programme  to  support  countries  in  the  establishment  of  essential  drug  policies. 
Its  aim  is  to  help  assure  the  regular  availability of  essential  drugs  of  good 
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the  UNICEF  to  support  the  provision of  essential  drugs  for  primary  health  care 
in  developing  countries.  UNICEF  has  widespread  operational  activities  in 
most  developing  countries  and  concentrates  mainly  on  procurement  and 
distribution. 
7.  The  cost  of  drugs  for  developing  countries  gives  rise to deep  concern.  In 
addition  to  Lacking  financial  resources  in  general,  these  countries  have 
·severely  limited  amounts  of  convertible  currency  for  drug  procurement. 
Recent  experience  with  international  tenders  for  generic  drugs  in  developing 
countries  has  been  very  encouraging;  thanks  to  purchasing  larger quantities 
required  for  a  longer  period  of  time,  and  thus  benefitting  from  the  economies 
of  scale.  But  greater  efforts are  required  to  help  Third  World  countries 
to  overcome  their  convertible  currency  problems  as  they  relate  to  drug  imports. 
W.H.O.  in  close  cooperation  with  the  UNICEF  Packing  and  Assembly  Centre 
(UNIPAC),  collaborates  with  countries  to  improve  procurement  procedures. 
Tender  documents,  price  Lists  and  names  of  reputable  suppliers are available 
on  request.  UNIPAC  has  managed,  through  international  competitive  bidding, 
to  achieve  considerable  reductions  in  the  prices  of  about  140  essential  drugs. 
Countries  can  obtain essential  drugs  at  these  low  prices  through  a  re-imbursement 
scheme,  which,  however,  requires  prepayment  in  'hard'  currency.  A financing 
agreement  is  being  developed  whereby  countries  with  essential  drugs  programmes 
will  be  provided  with  credit  for  drug  procurement.  In  some  instances,  Local 
currency  may  be  accepted  in  part  payment. 
8.  Once  drugs  are  either  manufactured  or  imported,  they  have  to  be  properly  stored 
and  distributed.  Problems  of  storage  and  distribution  include  pilfering, 
waste,  inappropriate  builings,  insufficiency  of  shelf  space  to  store  drugs  and 
equipment,  Lack  of  staff  trained  in  modern  storage  and  distribution 
management,  shortage  of  fuel  and  poor  roads. 
txperience  in  a  few  countries  has,  however,  showed  that  it  is possible  to 
improve  both  storage  and  distribution.  Essential  drugs  are,  in  fact,  reaching 
the  most  distant  units  in  several  countries  on  a  regular  basis  and  with  a 
minimum  of  wastage.  The  ration  kit  system  used  in  Kenya  and  Tanzania,  appears 
to  be  a  feasible  approach.  Durg  quantities  tailored to  the  needs  to  a  health 
unit  and  designed  for  a  specific  number  of  patients  are  pre-packed  in  sealed 
boxes.  New  kits  are  supplied  on  the  basis  of  attendance  rates  rather  than  on 
monthly  or  quarterly  schedules  that  ignore  the  number  of  patients  treated. 
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material  and  Labour  needed.  But  this  additional  cost  would  seem  to  be 
more  than offset  by  the  reduction  in waste  and  theft  of  drugs. 
w.H.O.,  together  with  UNICEF,  collaborate  with  several  countries  in  improving 
storage  and  distribution  systems  and  training store managers  in better 
techniques.  Manuals  and  teaching  material  on  storage  and  logistics  have  been 
aeveloped  and  the first  few  workshops  have  taken  place. 
Research  to  determine  the  stability of  drugs  stored under  tropical  conditions 
is  under  way. 
9.  The  complex~ty of  the  international  drug  market  and  the  urgency  with  which 
messages  sometimes  need  to  be  relayed  requires  efficient  international 
channels  of  communication  between  national  drug  regulatory  authorities. 
International  systems  of  exchange  of  information  relieve  regulatory  authori-
ties  in  developing  countries  of  the  need  to  undertake  fully  independent 
assesments  of  the  drugs  registered  under  their aegis.  However,  no  mechanism 
for  international  exchange  of  regulatory  information  can  operate effectively 
where  there  is  no  indigenous  system  of  drug  registration. 
To  introduce  rationality  into  the  naming  of  drug  substances  W.H.O.  assigns 
internationally recognised  generic  names  (International  Nonproprietary  Names 
- INNs).  It  has  established  an  International  Drug  Monitoring  Scheme  on  the 
adverse  effects  of  drugs.  It  provides  specifications  in  the  international 
Pharmacopoeia  for  assuring  the  quality  of  drug  substances.  It plans  and 
co-sponsors  the  biennial  International  Conference  of  Drug  Regulatory  Authorities 
through  a  network  of  national  information officers  it disseminates  details  of 
restrictive national  reguratory  decis·ions  taken  in  respect  of  marketed drugs, 
when  necessary  by  telex.  It  provides  evaluated  information  on  national  regu-
Latory  decisions  through  the  W.H.O.  Drug  Information Bulletin,  and  work  is  in 
hand  to  produce  a  W.H.O.  model  formulary  based  on  the  model  list of  essential 
drugs.  It  has  also  developed  a  simplified  system of  drug  quality  control  that 
could  be  applied  by  countries  with  even  the  most  Limited  resources. 
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for  improving  their  drug  situation.  If  they  apply  them  properly,  they  could 
have  better access  to objective  information  on  drugs,  improve  their 
manufacturing  practices  and  qualify  control  measures,  ensure  that  the  drugs 
they  import  conform  to  the  standards  of  the  exporting  country,  introduce  sound 
drug  policies  to  ensure  that  all their  people  have  regular  access  to  the 
essential  drugs  they  need,  and  reduce  the  cost  of  importing  drugs.  In  short, 
they  could  take  significant  steps  towards  a  rational  use  of  drugs. 
This  of  course  requires  a  change  in political will  and  a  huge  increase  in  the 
provision of  resources  (both  human  and  financial)  from  the  developed  to  the 
developing  world. 
The  aim  is  Health  for  All  by  the  year  2000.  It  is  not  an  impossible  dream. 
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tabled by  Ms  QUIN  and  Mr  ADAM 
on  the  export  of  drugs  from  the  EEC  to  the 
countries  of  the  Third  World  (doc.  2-565/84) 
THE  EUROPEAN  PARLIAMENT, 
ANNEX 
A  recognising  the  importance  of  the  EEC  in  the  world  trade  in  drugs, 
B  concerned  at  reports  that Tnrd  World  countries,  as  a  result  of  drug 
companies'  marketing  methods,  often purchase  inessential yet 
expensive  drugs  instead of  essential  (and  often  cheaper)  ones, 
c  noting  with  approval  the  example  of  the  Bangladeshi  government  which, 
in  1982,  announced  a  new  drug  policy giving  priority to drugs 
essential  tor  public  health  needs, 
D  considering  that  the  European  Community,  by  virtue of  its aid and 
trade  programme,  needs  to do  all  it  can  to  help  promote  improved 
standards  of  health  care  and  the  treatment  of  diseases  in  the  Third 
World, 
E  concerned  that  manufacturers  do  not  always  seem  to apply  the  same 
standards  in  drug  sales  to the  Third  World  as  those  which  they  conform 
to  in  developed  countries, 
1.  Calls  on  its  competent  Committee  to  examine  the  situation on  the  world 
drug  market  as  it affects developing  countries  and  to put  forward 
proposals  to enable  the  Community  to  make  an  effective contribution  to 
rational  drug  use  in  the  Third  World; 
2.  Instructs  its President  to  forward  this  resolution  to  ~he Commission  and 
Council. 
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(Rule  101  of  the  Rules  of  Procedure) 
of  the  Committee  on  Development  and  Cooperation 
Draftsman:  Mr  Anthony  Simpson 
On  18  December  1984,  the  Committee  on  Development  and  Cooperation  appointed 
Mr  Simpson  draftsman  of  the  opinion. 
The  Committee  considered  the draft  opinion  at  its  meetings  of  24  April  1985 
and  22  May  1985.  It  adopted  the  draft  opinion  on  22  May  1985  by  17  votes  to  1 
with  no  abstentions. 
The  following  took  part  in  the  vote:  Mr  Bersani, vi ce-c hai rman,  acting 
chairman;  Mr  de  Courcy  Ling,  vice-chairman;  Mr  Simpson,  draftsman;  Mr  Baget 
Bozzo,  Mrs  Barbarella  (deputising  for  Mr  Pajetta);  Mrs  Cinciari  Rodano,  Mrs  De 
Backer-Van  Ocken,  Mr  Jackson,  Mr  Lemmer,  Mr  Luster,  Mr  d'Orrnesson,  Mr  Prout 
<deputising  for  Mrs  Daly);  Mrs  Rabbethge,  Mrs  Schmit,  Mrs  Simons,  Mr  Trivelli, 
Mr  Ulburghs  (deputising  for  Mr  Pannella);  Mr  Verbeek. 
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The  Committee  on  Development  and  Cooperation 
- having  regard  to  the  motion  for  a  resolution  tabled  by  Mrs  Quin  and  Mr  Adam  on 
the  export  of  drugs  from  the  EEC  to  the  countries  of  the  third  world  (Doc. 
2-565/84), 
A.  Noting  that  developing  countries  are  overwhelmingly  dependent  for  drug 
requirements  on  imports  from  industrialised  countries, 
B.  Having  regard  to  resolution  adopted  on  17  May  1984  by  the  World  Health 
Assembly  in  Geneva  calling  for  a  meeting  of  experts  to  be  held  in  1985  to 
discuss  ways  of  ensuring  the  rational  use  of  medicines  and  the  role  of 
marketing  practices  in  this  field,  particularly  in  the  developing 
countries, 
C.  Noting  that  the  European  Community  is  by  far  the  Largest  exporter  among  the 
industrialised  countries  of  pharmaceutical  products  to  the  Third  World, 
D.  Noting  that  aggressive  sales  campaigns  conducted  by  certain pharmaceutical 
companies  may  encourage  developing  countries  to  import  expensive, 
non-essential  drugs, 
E.  Noting  that  the  World  Health  Organisation  has  prepared  a  list  of  some  220 
essential  medicines  as  part  of  its  Action  Programme  on  Essential  Drugs, 
F.  Noting  that  in  1982  the  government  of  Bangladesh  formulated  a  new  drug 
policy  giving  priority  to  drugs  deemed  essential  for  health  ne~ds, 
1.  Calls  for  full  exchange  of  information  with  the  authorities  in  developing 
countries  concerning  drugs  banned  or  severely  restricted  in  any  of  the 
Community  Member  States~ 
2.  Proposes  that  developing  countries,  particularly  the  Least  developed, 
should  be  encouraged  to  give  priority  to  imports  of  those  drugs  deemed  most 
essential,  and  for  this  purpose  to  draw  up  lists  thereof; 
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in  International  Commerce  as  a  useful  method  of  guaranteeing  the  quality  of 
drugs  and  urges  importing  developing  countries  to  make  more  use  of  its 
provisions; 
4.  Insists  on  drugs  manufactured  for  export  being  produced  to  the  same 
standards  as  drugs  intended  for  sale  in  the  country  of  manufacture; 
5.  Calls  on  drug  producers  to  Label  all  medicines  exported  to  developing 
countries  clearly,  in  a  way  understandable  to  those  concerned,  and  insists 
on  indications  and  counter-indications  being  indicated  as  fully  as  on  drugs 
intended  for  use  in  industrialised  countries; 
6.  Notes  that  in  1981  the  International  Federation  of  Pharmaceuticals 
Manufacturers'  Associations  (IFPMA)  drew  up  a  voluntary  code  of  marketing 
practice  with  regard  to  drug  exports,  but  regrets  that  reports  indicate 
that  this  code  has  not  been  fully  effective  due  to  inadequate  monitoring; 
7.  Consequently  requests  the  Committee  on  the  Environment,  Public  Health  and 
Consumer  Protection  and  the  Commission  of  the  European  Communities  to 
take  all  necessary  steps  to  ensure  a  more  effective  international  code  of 
conduct  for  drug  exports  to  developing  countries,  in  particular with  regard 
to  marketing practices,  advertising  and  Labelling;  a  firm  timetable  should 
be  established for  the  entry  into  force  of  this  code  of  conduct; 
8.  Notes  that  such  a  code  of  conduct  could  not  be  effective  unless  it were 
established  on  an  international  basis  under  the  aegis  of  a  body  such  as  the 
World  Health  Organisation,  and  in  consultation  with  the pharmaceutical 
companies  concerned; 
9.  Calls  on  the  Commission  and  Council  of  the  European  Communities  and  the 
ACP-EEC  institutions  to  support  the  efforts of  UNIDO  to  develop 
pharmaceutical  industries  in  the  third world,  inter alia  by  favouring  the 
formation  of  joint  ventures,  where  appropriate,  between  Community  and  ACP 
companies  operating  in  the  pharmaceutical  sector; 
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programme  "Science  and  Technology  for  Development"  is  concerned  with 
medicine,  health  and  nutrition  in  the  tropical  zones;  asks  that  further 
programmes  of  this  nature  will  be  initiated  in  the  future; 
11.  Believes  that  in  developing  countries  priority  should  be  given  to primary 
public  health  care,  especially  vaccination  and  immunisation,  disease 
prevention  and  eradication,  and  education  in  health ·and  hygiene;  feels  that 
the  pharmaceutical  companies  should  be  encouraged  to  make  a  particular 
effort  to  develop  appropriate  Low-cost  drugs  of  high  standard,  while  noting 
that  many  already  do  so,  and  asks  the  Committee  on  the  Environment  to 
monitor  the. follow-up; 
12.  Believes  that  the  use  of  traditional  medicines  can  make  an  important 
contribution  to  health  in  developing  countries,  and  that  the  production  of 
such  medicines  should  be  encouraged. 
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The  European  Community  is  a  major  drug  producer  and  exporter,  being 
responsible  for  some  25%  of  world  drug  production  and  50%  of  world  trade  in 
pharmaceuticals.  In  1983,  the  Last  year  for  which  statistics are  available,  the 
Community  exported  pharmaceutical  products  and  medicines  to  a  value  of  5329 
mECU,  of  which  49%  <valued  at  2613  mECU)  were  exported  to  developing 
countries. (1)  It  should  be  emphasised,  however,  that  the  European  Community  is 
not  by  any  means  the  only  major  drug  exporter.  During  the  same  year  the  US 
exported  drugs  valued  at  643  mECU  to  developing  countries,  while  exports  from 
Switzerland  and  Japan  to  the  third  world  amounted  to  479  mECU  and  142  mECU 
respectively. (2)  In  addition  COMECON  exports  drugs  to  the  developing  world,  as 
do  other  non-Community  European  countries. 
The  third  world  has  a  growing  need  of  drugs,  both  in  the  form  of  human  and 
veterinary  medicines.  An  overwhelming  proportion  of  these  products,  some  89%, 
are  produced  in  industrialised  countries.  Most  are  manufactured  by  major  drug 
companies,  many  of  which  are  organised  on  a  transnational  basis.  It  is  obvious 
that  drug  companies  can  only  continue  to  operate  if  they  make  an  overall  profit 
on  their operations,  and  that  manufacturing  costs,  as  well  as  research  and 
development  expenses,  must  be  recovered  from  sales. 
At  the  same  time  as  a  growing  number  of  developing  countries  are 
experiencing  food  crises  connected  with  drought  and  the  spread  of  desertific-
ation,  obliging  them  to  devote  an  increasingly  higher  proportion  of  national 
income  to  food  imports,  the  need  for  drugs  increases  as  the  health  situation  of 
the  population  deteriorates.  Meanwhile  less  finance  is  available  for  drug 
purchases.  Under  these  circumstances  developing  countries  have  to  make 
difficult  decisions  regarding  what  drugs  should  be  purchased. 
Many  observers  of  developing  countries,  and  most  particularly  of  the 
poorest  LDCs,  have  commented  on  hospitals  and  health  centres  operating  without 
medicines.  This  is  generally  due  to  Lack  of  hard  currency  with  which  to  import 
pharmaceutical  products.  At  the  same  time  certain  drug  companies  have 
encouraged  the  authorities  in  developing  countries  to  purchase  a  very  wide  range 
of  pharmaceuticals  at  considerable  cost. 
( 1 ) 
Source  Eurostat 
(2) 
Source  COMTRADE  (UNO  Geneva) 
- 25  - PE  96.643tfin. In  1982  the  government  of  Bangladesh  formulated  a  new  drug  policy  which 
gave  priority  to  a  restricted  List  of  essential  drugs,  while  restricting  imports 
of  what  were  considered  inessential,  which  were  generally  among  the  more 
expensive  products. 
The  World  Health  organisation  CWHO)  has  drawn  up  a  List  of  some  220 
essential  medicines  which  - if  used  rationally  and  effectively  as  part  of  an 
overall  national  health  strategy  - would  help  to  overcome  the  most  serious 
I 
health  problems  caused  or  aggravated  by  Lack  of  medicines  in  developing 
countries.  ALL  these drugs  are  of  proven  therapeutic  value,  but  should 
nevertheless  only  be  prescribed  when  really  necessary.  Over  95%  of  these  drugs 
can  be  produced  as  off-patent  generic  medicines  instead of  expensive  branded 
drugs,  and  bulk  purchasing  can  reduce  costs  still further.  The  Committee  on 
Development  and  Cooperation  sees  the  Logic  behind  the  establishment  of  lists of 
essential priority  drugs  by  poor  third world  countries,  while  recognising  that 
the  circumstances  vary  from  country  to  country  according  to  the  overall  health 
situation  and  the  availability  of  foreign  exchange. 
It  is  the  Committee's  belief  that  priority  must  be  given  to  primary  public 
health  care  including  vaccination  and  immunisation,  disease  prevention  and 
eradication  and  education  in  health  and  hygiene.  The  development  of  low-cost 
pharmaceutical  products  required  therefor  should  be  accorded  a  particular 
priority  by  drug  manufacturers.  , 
The  Committee  on  Development  and  Cooperation  feels  strongly  that  drugs 
produced  for  export  must  be  made  to  the  same  standards  as  drugs  intended  for 
sale  ir,  the  country  of  manufacture.  It  is  not  acceptable  to  sell  drugs  in  third 
world  countries  that  would  be  banned  in  the  industrialised world.  Most  of  the 
major  Community  drug  producers  are  members  of  the  International  Federation  of 
Pharmaceuticals  Manufacturers'  Associations  (IFPMA) •.  In  1981  this  organisation 
drew  up  a  voluntary  code  of  marketing  practice  according  to  which  signatories 
undertake  "to  ensure  that  all  products  .... have  full  regard  to  the  needs  of 
public  health".  In  addition,  members  are  required  to  "provide  scientific 
information  with  objectivity  and  good  taste,  with  scrupulous  regard  for  truth, 
and  with  clear  statements  with  respect  to  indications,  contra-indications, 
tolerance  and  toxicity."  In  practice  it would  appear  that  this  voluntary  code 
is  not  monitored  or  enforced,  and  that  abuses  in  drug  marketing  continue,  even 
by  companies  that  have  agreed  to  the  IFPMA  code. 
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and  adequately-monitored  code  of  conduct  for  companies  exporting  pharmaceutical 
products  to  ensure  against 
i)  excessively  aggressive  sales  campaigns  in  favour  of  expensive  non  essential 
drugs 
11  the  exportation  of  sub-standard  drugs  and  products  that,  for  Long-term 
health  reasons,  are  not  permitted  in  industrialised  countries 
iii)  inadequate  or  misleading  indications  or  labels,  as  well  as  indications 
and/or  Labels  that  are  not  readily  understood  by  drug  users; 
It  must  be  pointed  out  however,  that,  though  a  major  source  of  drugs  for 
export  to  the  third world,  the  European  Community  is  by  no  means  the  only 
exporter  Csee  first  paragraph  of  this  explanatory  statement).  It  is  thus  not 
possible  for  the  European  Community  acting  in  isolation  to  prevent  abuses  by 
drug  exporters.  Futhermore,  as  most  of  the  major  drug  companies  are 
transnational,  if  restrictions  were  to  be  imposed  on  a  company's  operations  from 
the  European  Community,  it  would  be  easy  for  the  same  company  to  continue 
manufacturing  restricted  drugs  for  export  in  its factories  situated outside  the 
Community.  It  is  thus  necessary  for  a  more  effective  code  of  conduct  for 
pharmaceutical  marketing  to  be  drawn  up 
Ci)  in  close  collaboration  with  the  companies  concerned 
Cii)  on  a  broad  international  basis,  under  the  aegis  of  a  body  such  as  the  World 
Health  Organisation. 
Medicines  which  have  been  banned  in  Europe  sometimes  continue  to  be 
exported  to  developing  countries.  The  Committee  on  Development  and  Cooperation 
believes  that  the  authorities  of  developing  countries  should  be  fully  informed 
when  any  drugs  are  banned  or  severely  restricted  in  a  Member  State.·  Such 
information  should  be  provided  before  these  products  are  exported,  along  with 
the  reasons  for  imposing  restrictions. 
Some  of  the  problems  could  be  solved  if  more  drugs  were  produced  in 
developing  countries.  At  present  only  11%  of  world  pharmaceutical  production  is 
carried  out  in  developing  countries,  and  this  is  mostly  concentrated  in  the  more 
developed  third world  nations,  particularly Brazil,  India,  Mexico,  Egypt, 
Argentina,  Colombia  and  Venezuela.  Most  of  this  industrial  activity  consists  of 
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- 27  -further  processing  or  packaging  of  products  imported  in  bulk.  The  ~.N. 
Industrial  Development  Organisation  CUNIDO)  has  prepared  a  programme  to  foster 
the  development  of  the  pharmaceutical  industry  in  the  Third  World,  but  little 
has  been  achieved  to  date.  It  is  essential  that  the  pharmaceutical  industty  in 
the  third  world  should  concentrate  on  the  production  of  drugs  deemed  essential. 
The  Community  institutions  should  encourage  this  initiative,  perhaps  by 
favouring  joint  ventures  between  Community  and  ACP  industries  through  the  good 
offices  of  the  Centre  for  Industrial  Development. 
In  conclusion  the  Committee  on  Development  and  Cooperation  recognises  the 
value  of  Lists  of  priority drugs  for  the  poorer  developing  countries,  with 
corresponding  restrictions  on  expensive  non-essential  medicines,  and  calls  on 
the  Committee  on  the  Environment,  Public  Health  and  Consumer  Protection  to 
examine  the  situation of  the  world  drug  market  as  it  affects  developing 
countries,  to  investigate  the  means  whereby  a  more  effective  and  adequately 
monitored  international  code  of  conduct  can  be  established,  and  to  put  forward 
proposals  to  enable  the  Community  to  make  a  positive  contribution  to  rational 
drug  use  in  the  third world. 
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